Market Overview

Study Showing Potential for microRNAs as Biomarkers for Heart Failure Prognosis Published in European Journal of Heart Failure

Rosetta Genomics, Ltd. (NASDAQ: ROSG) announces that results from a joint study by researchers at Rosetta Genomics and the Department of Cardiovascular Medicine, Lady Davis Carmel Medical Center in Haifa, Israel, show that elevated serum levels of specific microRNAs identify systolic heart failure patients and correlate with important clinical prognostic parameters.

In this study, researchers characterized the levels of microRNAs in the sera of chronic systolic HF patients versus controls, and assessed the possible correlation between elevation in the levels of specific microRNAs and clinical prognostic parameters in HF patients.

The levels of 186 microRNAs were measured in the sera of 30 stable chronic systolic HF patients and 30 controls using qRT-PCR. The differences in microRNA levels between the two groups were characterized and a score, based on the levels of four specific microRNAs with the most significant increase in the HF group (miR-423-5p, miR-320a, miR-22, and miR-92b), was defined.

Posted-In: News FDA

 

Related Articles (ROSG)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters